about
sameAs
P3355
Q21851559-19FFDB92-9174-451C-842C-8F740EEAA8A9Q21851559-2A87A28C-2588-49CA-91F5-3524B928AE45Q21851559-3D3490AA-D7F1-4D20-9A75-405A53B8D5B3Q21851559-DCFAAA4D-07F6-4481-8AAE-FE2EE09AC945Q28371521-B9C1360E-9A74-4A61-9269-7094E6EA01AAQ28371521-FE0177C1-6142-4D09-AB8E-17E951DF8E27Q28531477-7D7E9F37-5D65-4139-ACD9-6A4195988170Q28531477-AC697309-1BC7-4A55-8EE2-2BD048C7B13EQ28531477-D3D7C14F-BC38-4E0E-8FA3-8FE90DBF319CQ28531477-F9858BF9-698C-4242-BC17-DB79B109CE33Q42302375-8C9F32CA-CEB5-4011-BEDC-10A436E82D9FQ42302375-CE85A7C8-CF6A-48D7-AB87-81D40D644BDA
P3354
description
combination therapy
@en
name
Dabrafenib / Trametinib combination therapy
@en
type
label
Dabrafenib / Trametinib combination therapy
@en
altLabel
Combination of Dabrafenib and Trametinib
@en
prefLabel
Dabrafenib / Trametinib combination therapy
@en